Talk:Glucose-dependent insulinotropic polypeptide
Discussion page·4 threads·no archives
This is the discussion page for the article Glucose-dependent insulinotropic polypeptide. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.
GIP-incompetence: sourcing and terminology
The term "GIP-incompetence" appears in the article but I cannot find it used that way in the primary literature — most reviews call it "GIP resistance" or "loss of GIP secretory response". The former term may be original research. — — Chromatokid (talk) 10:22, 15 April 2026 (UTC)
That is a fair challenge. I found the term in one review but not consistently used. Reworded to "impaired beta-cell responsiveness to GIP" which is more directly sourced. — — Ref_Desk_Ron (talk) 14:48, 15 April 2026 (UTC)
Adipose-tissue mechanism remains speculativeResolved
§Therapeutic exploitation claims that dual agonism works partly through "active GIP-receptor antagonism at the adipocyte". This reads as fact but the sentence admits evidence is limited. Reworded to clearly frame this as a hypothesis. — — AnalyticalAnnie (talk) 11:05, 19 March 2026 (UTC)
Clearer now. The distinction between restored responsiveness and active antagonism is important for a reader trying to distinguish drug mechanism. ✓ Done — — Peptide_Pete (talk) 13:40, 19 March 2026 (UTC)
Requested move: → GIPRequested move
Propose moving to GIP — it is the abbreviation that appears in the primary literature and in every major review, and the expanded form is rarely used as a standalone title. — — MoveRequestMio (talk) 09:30, 18 February 2026 (UTC)
Oppose. The expanded name is the formal International Nonproprietary Name (INN) and the article should carry that in the title. The redirect exists and works. — — NPOV_Nadia (talk) 11:15, 18 February 2026 (UTC)
Closing as not moved. Consensus against moving. The formal INN is the appropriate title per house style for pharmacological entities. — — Ref_Desk_Ron (talk) 10:45, 20 February 2026 (UTC)
Fasting concentration range — should this be in the infobox?Done
Proposal: add "Fasting plasma concentration: 40–60 pmol/L" to the infobox, for consistency with the GLP-1 article. — — BaselineBex (talk) 08:11, 28 January 2026 (UTC)
It is already mentioned in the lead with context. Infobox entries read as settled facts; the range is assay-dependent and needs the caveats that live in the text. Better left as is. — — AnalyticalAnnie (talk) 10:33, 28 January 2026 (UTC)
Fair enough. Keeping it in the main text where the assay caveats are properly explained makes more sense than elevating it to infobox status where it would read as settled fact. ✓ Done — — BaselineBex (talk) 12:05, 28 January 2026 (UTC)